MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
MetaVia (Nasdaq: MTVA) announced that data from its Phase 2a clinical trial of DA-1241, a novel GPR119 agonist, will be presented as a late-breaking poster at the EASL Congress 2025 in Amsterdam (May 7-10, 2025). The presentation will focus on the drug's hepatoprotective and glucose-regulating effects in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH) from a 16-week randomized placebo-controlled trial.
The presentation titled 'DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients' will be delivered by Dr. Rohit Loomba from the University of California, San Diego. The poster will be available on MetaVia's website following the presentation.
MetaVia (Nasdaq: MTVA) ha annunciato che i dati del suo studio clinico di Fase 2a su DA-1241, un nuovo agonista del GPR119, saranno presentati come poster late-breaking al Congresso EASL 2025 ad Amsterdam (7-10 maggio 2025). La presentazione si concentrerà sugli effetti epatoprotettivi e sul controllo della glicemia del farmaco in pazienti con presunta steatoepatite associata a disfunzione metabolica (MASH), in uno studio randomizzato controllato con placebo della durata di 16 settimane.
La presentazione, intitolata 'DA-1241, un agonista del GPR119, dimostra effetti epatoprotettivi e di regolazione della glicemia in uno studio randomizzato controllato con placebo di 16 settimane in pazienti con presunta MASH', sarà tenuta dal dott. Rohit Loomba dell'Università della California, San Diego. Il poster sarà disponibile sul sito web di MetaVia dopo la presentazione.
MetaVia (Nasdaq: MTVA) anunció que los datos de su ensayo clínico de fase 2a de DA-1241, un novedoso agonista del GPR119, serán presentados como póster late-breaking en el Congreso EASL 2025 en Ámsterdam (7-10 de mayo de 2025). La presentación se centrará en los efectos hepatoprotectores y reguladores de glucosa del medicamento en pacientes con presunta esteatohepatitis asociada a disfunción metabólica (MASH), en un ensayo aleatorizado controlado con placebo de 16 semanas.
La presentación titulada 'DA-1241, un agonista del GPR119, demuestra efectos hepatoprotectores y regulación glucémica en un ensayo aleatorizado controlado con placebo de 16 semanas en pacientes con presunta MASH' será impartida por el Dr. Rohit Loomba de la Universidad de California, San Diego. El póster estará disponible en la página web de MetaVia tras la presentación.
MetaVia (나스닥: MTVA)는 새로운 GPR119 작용제인 DA-1241의 2a상 임상시험 데이터를 2025년 5월 7일부터 10일까지 암스테르담에서 열리는 EASL 학술대회 2025에서 레이트 브레이킹 포스터로 발표할 예정이라고 발표했습니다. 발표는 대사 기능 장애 연관 지방간염(MASH)으로 추정되는 환자들을 대상으로 한 16주간 무작위 위약 대조 시험에서 약물의 간 보호 및 혈당 조절 효과에 초점을 맞출 것입니다.
'DA-1241, GPR119 작용제, 추정된 MASH 환자 대상 16주 무작위 위약 대조 시험에서 간 보호 및 혈당 조절 효과 입증'이라는 제목의 발표는 캘리포니아 대학교 샌디에이고의 로히트 룸바 박사가 진행합니다. 발표 후 포스터는 MetaVia 웹사이트에서 확인할 수 있습니다.
MetaVia (Nasdaq : MTVA) a annoncé que les données de son essai clinique de phase 2a sur DA-1241, un nouvel agoniste du GPR119, seront présentées sous forme de poster late-breaking au Congrès EASL 2025 à Amsterdam (du 7 au 10 mai 2025). La présentation portera sur les effets hépatoprotecteurs et régulateurs de la glycémie du médicament chez des patients présumés atteints de stéatohépatite associée à une dysfonction métabolique (MASH), issus d’un essai randomisé contrôlé par placebo de 16 semaines.
La présentation intitulée « DA-1241, un agoniste du GPR119, démontre des effets hépatoprotecteurs et régulateurs de la glycémie dans un essai randomisé contrôlé par placebo de 16 semaines chez des patients présumés atteints de MASH » sera donnée par le Dr Rohit Loomba de l’Université de Californie à San Diego. Le poster sera disponible sur le site web de MetaVia après la présentation.
MetaVia (Nasdaq: MTVA) gab bekannt, dass Daten aus der Phase-2a-Studie zu DA-1241, einem neuartigen GPR119-Agonisten, als Late-Breaking-Poster auf dem EASL-Kongress 2025 in Amsterdam (7.-10. Mai 2025) präsentiert werden. Die Präsentation konzentriert sich auf die hepatoprotektiven und glukoseregulierenden Wirkungen des Medikaments bei Patienten mit vermuteter metabolischer Dysfunktions-assoziierter Steatohepatitis (MASH) aus einer 16-wöchigen randomisierten, placebokontrollierten Studie.
Die Präsentation mit dem Titel 'DA-1241, ein GPR119-Agonist, zeigt hepatoprotektive und glukoseregulierende Effekte in einer 16-wöchigen randomisierten, placebokontrollierten Studie bei vermuteten MASH-Patienten' wird von Dr. Rohit Loomba von der University of California, San Diego, gehalten. Das Poster wird nach der Präsentation auf der Website von MetaVia verfügbar sein.
- None.
- None.
- Title: DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients
- Presenting Author: Rohit Loomba, MD, MHSc, Professor of Medicine in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at University of
California ,San Diego . - Abstract Number: LB2517
- Final Abstract ID:
LBP-005 - Session: Late Breaker Posters
- Session Date: May 7-10, 2025
- Presentation Start: May 7, 2025, 8:30 am CET
A copy of the poster will be available on the Posters section of the MetaVia website after the presentation.
About DA-1241
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase 1a, 1b and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-announces-late-breaking-poster-presentation-on-da-1241-at-the-easl-congress-2025-302435642.html
SOURCE MetaVia Inc.
FAQ
What are the key findings of MetaVia's (MTVA) Phase 2a trial for DA-1241 in MASH patients?
When will MetaVia (MTVA) present its DA-1241 clinical trial results at EASL 2025?
What is the mechanism of action of MetaVia's (MTVA) DA-1241 drug?
Where can investors find MetaVia's (MTVA) EASL 2025 poster presentation materials?
